182 related articles for article (PubMed ID: 29133553)
1. Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.
Bhalla P; Sultana S; Chiranjivi AK; Saikia AK; Dubey VK
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133553
[TBL] [Abstract][Full Text] [Related]
2. Novel Agents against Miltefosine-Unresponsive Leishmania donovani.
Das M; Saha G; Saikia AK; Dubey VK
Antimicrob Agents Chemother; 2015 Dec; 59(12):7826-9. PubMed ID: 26392497
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
5. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
6. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
7. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
[TBL] [Abstract][Full Text] [Related]
8. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
9. Possible mechanism of miltefosine-mediated death of Leishmania donovani.
Verma NK; Dey CS
Antimicrob Agents Chemother; 2004 Aug; 48(8):3010-5. PubMed ID: 15273114
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of ferrocenylquinoline as a potential antileishmanial agent.
Yousuf M; Mukherjee D; Pal A; Dey S; Mandal S; Pal C; Adhikari S
ChemMedChem; 2015 Mar; 10(3):546-54. PubMed ID: 25619822
[TBL] [Abstract][Full Text] [Related]
11. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Mishra J; Singh S
Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.
Shakya N; Sane SA; Haq W; Gupta S
Parasitol Res; 2012 Aug; 111(2):563-70. PubMed ID: 22392136
[TBL] [Abstract][Full Text] [Related]
14. Leishmania resistance to miltefosine associated with genetic marker.
Cojean S; Houzé S; Haouchine D; Huteau F; Lariven S; Hubert V; Michard F; Bories C; Pratlong F; Le Bras J; Loiseau PM; Matheron S
Emerg Infect Dis; 2012 Apr; 18(4):704-6. PubMed ID: 22469394
[No Abstract] [Full Text] [Related]
15. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
16. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
Shakya N; Sane SA; Vishwakarma P; Gupta S
Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca
Pinto-Martinez AK; Rodriguez-Durán J; Serrano-Martin X; Hernandez-Rodriguez V; Benaim G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061745
[No Abstract] [Full Text] [Related]
18. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of new adamantyl-substituted antileishmanial ether phospholipids.
Papanastasiou I; Prousis KC; Georgikopoulou K; Pavlidis T; Scoulica E; Kolocouris N; Calogeropoulou T
Bioorg Med Chem Lett; 2010 Sep; 20(18):5484-7. PubMed ID: 20719503
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
